DeepMed Research

INSTITUT CLAUDIUS REGAUD

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.claudiusregaud.fr

Clinical Trials

Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment

Not Applicable

Completed

Conditions: Solid Tumors

Interventions: Other: Telephone follow-up nursing device

First Posted Date: 2015-12-02

Last Posted Date: 2018-03-02

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 200

Registration Number: NCT02619045

Locations: 🇫🇷
Institut claudius regaud, Toulouse, France

Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma

Phase 4

Completed

Conditions: Metastatic Renal Cell Cancer

Interventions: Drug: Sunitinib
Drug: Pazopanib

First Posted Date: 2015-09-22

Last Posted Date: 2021-01-12

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 47

Registration Number: NCT02555748

Locations: 🇫🇷
CHU DE BORDEAUX - Hôpital Saint-André, Bordeaux, France
🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
CHU DE LIMOGES - Hôpital Dupuytren, Limoges, France

and more 5 locations

Therapeutic Nipple Sparing Mastectomy.

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Procedure: Nipple sparing mastectomy

First Posted Date: 2014-12-09

Last Posted Date: 2024-12-24

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 450

Registration Number: NCT02311959

Locations: 🇫🇷
Hôpital privé Drôme Ardèche, Guilherand-Granges, France
🇫🇷
Clinique du Mail, La Rochelle, France
🇫🇷
Pôle santé Léonard de Vinci, Chambray-lès-Tours, France

and more 30 locations

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

Not Applicable

Completed

Conditions: Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm

Interventions: Procedure: Blood samples of 10 mL

First Posted Date: 2014-10-17

Last Posted Date: 2024-12-03

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 151

Registration Number: NCT02266420

Locations: 🇫🇷
Institut Regional Du Cancer Montpellier, Montpellier, France
🇫🇷
CH Emile ROUX, Le Puy-en-Velay, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 8 locations

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

Phase 2

Completed

Conditions: Advanced Urothelial Cancer
Metastatic Urothelial Cancer

Interventions: Drug: Fractionated Cisplatin
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2014-09-15

Last Posted Date: 2019-08-09

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 46

Registration Number: NCT02240017

Locations: 🇫🇷
Centre Francois Baclesse, Caen, France
🇫🇷
INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Paul Papin, Angers, France
🇫🇷
Chru Besancon - Hopital Jean Minjoz, Besançon, France

and more 15 locations

Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.

Phase 2

Completed

Conditions: Localized Prostate Cancer

Interventions: Radiation: Focal brachytherapy

First Posted Date: 2013-07-18

Last Posted Date: 2018-08-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 18

Registration Number: NCT01902680

Locations: 🇫🇷
Institut Claudius REGAUD, Toulouse, France

Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study

Not Applicable

Completed

Conditions: Glioblastoma

Interventions: Procedure: Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol

First Posted Date: 2013-06-07

Last Posted Date: 2018-08-27

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 21

Registration Number: NCT01872221

Locations: 🇫🇷
Institut Claudius REGAUD, Toulouse, France
🇫🇷
CHU Rangueil, Toulouse, France

Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer

Not Applicable

Terminated

Conditions: Lung Nodule
Non Small Cell Lung Cancer

Interventions: Device: PET/CT 4D imaging in a synchronized mode centered on the thorax.

First Posted Date: 2012-11-02

Last Posted Date: 2014-10-09

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 46

Registration Number: NCT01720186

Locations: 🇫🇷
Institut Claudius REGAUD, Toulouse, France

Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria

Phase 1

Terminated

Conditions: Metastatic Cancer (Different Solid Tumour Types)

Interventions: Drug: Pazopanib

First Posted Date: 2012-07-17

Last Posted Date: 2018-08-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 18

Registration Number: NCT01642017

Locations: 🇫🇷
Hôpital Saint André, Bordeaux, France
🇫🇷
Centre François BACLESSE, Caen, France
🇫🇷
Institut Claudius REGAUD, Toulouse, France

and more 1 locations

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Phase 4

Completed

Conditions: Breast Cancer

Interventions: Drug: Tamoxifen, Letrozole , Anastrozole, Exemestane

First Posted Date: 2012-06-06

Last Posted Date: 2018-03-05

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 39

Registration Number: NCT01612871

Locations: 🇫🇷
Institut Claudius REGAUD Toulouse, Toulouse, France
🇫🇷
Centre Val d'Aurelle - Paul Lamarque, Montpellier, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy